

## **RWANDA**

## **Support for Human Papillomavirus Vaccine (HPV)**

This Decision Letter sets out the Programme Terms of a Programme

1.	Country:	Rwanda							
2.	Vaccine gran	t number:		20-RWA-19	b-A				
3.	Date of Decis	ion Letter:	30 September 2019						
4.	Date of the Partnership Framework Agreement: 7 June 2013								
5.	Programme title:		New Vaccine Support (NVS), HPV, Routine (Fragility, emergencies and refugees policy)						
6.	Vaccine type:	ı I	Human Papillomavirus Vaccine						
7.	Requested product presentation and formulation of vaccine:  HPV Quadrivalent, 1 dose per vial, LIQUID								
8.	Programme Duration: 1 2020								
9.	Programme Budget (indicative): <sup>2</sup> (subject to the terms of the Partnership Framework Agreement, if applicable)								
		n/a	2020	2021	2022	2023	2024	Total <sup>2</sup>	
	Programme Budget (US\$)	n/a	7,000	-	-	-	-	7,000	
10.	Vaccine introduction grant  Not applicable								
11.	Product switch	ch grant	Not applicat	ole					
12.	Indicative An	cative Annual Amounts: <sup>3</sup> (subject to the terms of the Partnership Framework Agreement, if applicable)							
	Type of suppl purchased wi funds		n.	/a	20	20	202	1	
	Number of vaccine doses					1,500		-	
	Annual Amour	nts (US\$)		n/a		7,000		-	
13.	Procurement agency: UNICEF. The Country shall release its co-financing payments each								

year to UNICEF.

 $<sup>^{\</sup>rm 1}$  This is the entire duration of the programme.  $^{\rm 2}$  This is the total amount endorsed by Gavi for the entire duration of the programme.  $^{\rm 3}$  This is the amount that Gavi has approved.



14. Self-procurement: Not applicable

15. Co-financing obligations:

Not applicable

16. Operational support for campaigns:

Not applicable

17. Additional Reporting Requirements:

	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year:	
Vaccine stock levels including buffer stock     Number of children to be vaccinated, wastage rates, any	31 March 2020
<ul> <li>proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received</li> </ul>	15 May 2020
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat

18. Financial clarifications: Not applicable

19. Other conditions:

Not applicable

Signed by

On behalf of Gavi

Thabani Maphosa

Managing Director, Country Programmes

30 September 2019